Maggie L. Shaw

Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity.

Smarter therapies, evolving frailty tools, and more inclusive trials are finally extending myeloma's survival gains to older adults.

Rising global temperatures are silently driving a sedentary crisis, and the world’s most vulnerable populations are paying the steepest price.

Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, supporting potential pediatric label expansion.

Beyond progression-free survival, the combination of teclistamab and daratumumab hyaluronidase-fihj showed deep clinical responses, notes Ajay K. Nooka, MD, MPH.

Galleri trial data show liquid biopsy multicancer early detection tests may cut stage IV diagnoses, despite the missed primary end point.

Experts examine MFN pricing, the Great Healthcare Plan, ACA subsidies, PBM reform, and CMS talks in 2026.

MajesTEC-9 supports moving teclistamab earlier in myeloma treatment, with robust PFS and OS gains over standard care in the second-line setting, notes Roberto Mina, MD.

Early treatment for acute promyelocytic leukemia likely improves mother-baby outcomes, with treatment timing guiding safer delivery.

Ajai Chari, MD, discusses how the results of the MajesTEC-3 trial may translate to a real-world second-line population with multiple myeloma.

Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.

Domain Adaptation leverages lymphoma EHRs to better predict infection risk from treatment-related immune suppression in CLL, boosting Matthews correlation coefficient.

Teclistamab had received an accelerated approval in October 2022; the combination regimen is administered subcutaneously.

Patient-reported data can predict survival in leukemia, and integrating measuring tools improves care by prioritizing the patient's perspective.

Peter Voorhees, MD, explains how new daratumumab data shift smoldering multiple myeloma from watchful waiting to treatment.

The data in these posters address a central clinical question: can a topical JAK1/JAK2 inhibitor deliver robust efficacy while maintaining a reassuring safety profile?

Jody L. Green, PhD, explains how regulatory decisions shape medication safety amid uptake of OTC drugs.

Socioeconomic adversity in the perinatal period drives widening low birth weight gaps, fueling adverse pregnancy outcomes and deepening maternal and infant health inequities.

Nearly 3 million MA enrollees may lose plan coverage in 2026 as payment reforms drive market exits, hitting rural areas hardest and reshaping competition, explains Mark Meiselbach, PhD.

Treatment for multiple myeloma often confers a higher risk of subsequent cardiovascular disease, but the impact of medications for the latter in this setting is not fully understood.

Bhavana (Tina) Bhatnagar, DO, advocates for AI and diverse clinical trials to bridge equity gaps in precision oncology and value-based care.

Tina Bhatnagar, DO, speaks to the importance of diversity in clinical trials and the need to remove barriers, enroll underrepresented backgrounds, and reflect real-world health conditions.

Mark Meiselbach, PhD, at Johns Hopkins, explains Medicare Advantage market corrections, Star Rating System pressures, and rural plan exits.

Digital health record integration boosts medication safety, as OTC use rivals prescription use in chronic care management, found a new study led by Jody L. Green, PhD, Uprise Health.

A new study finds higher radiation to key brain stem cell regions in NSCLC brain metastases tied to shorter survival.

The FDA approved acalabrutinib and venetoclax, a fixed‑duration all‑oral CLL/SLL first‑line combo, based on phase 3 AMPLIFY trial data.

Medicare Advantage beneficiaries face forced disenrollment in 2026 as plan exits drive coverage termination, pushing millions toward traditional Medicare and Part D’s $2100 cap.

A new Mayo Clinic study questions the benefit of implantable cardioverter-defibrillator use to treat patients with transthyretin cardiac amyloidosis.

These new data show that 64.8% of US adults take at least 1 prescription medication each year.

NHANES data reveal a US sleep crisis: Chronic sleep deprivation gaps tied to education, BMI, and food security, via Blinder-Oaxaca decomposition.